Biomedical Diagnostic Research, Inc.

Biomedical Diagnostic Research, Inc. was founded in 1999.

The primary goal of the laboratory was to design a commercially viable test for serum Thiols.. This study was done in conjunction with The University of Lund in Lund, Sweden. Under the scrutiny of Dr. Ronald Pero, the laboratories were able to correlate their research efforts validating a micro-titer plate assay that would be able to rapidity analyze the total Thiol proteins. This was accomplished and validated in October 2002. The Serum Protein Thiol Test is now available through Biomedical Diagnostic Research Labs.

The laboratory is located near Cleveland, Ohio in the township of Chesterland.

BDR Principals - Dr. Ronald Pero

Dr. Ronald Pero is one of the world's leading authorities on DNA repair, with over 30 years of extensive research. He has many books  published, as well as having more than 250 peer-reviewed articles on the subject.

Dr. Pero has also been the head of Molecular Ecogenetics at the University of Lund, Sweden (1993), where he was also Director of the Cancer Identification Division developing applications for the  identification of individuals at risk for cancer.

Dr. Pero's years of research led him to discover and create a key ingredient of the Optigene product line: C-MED-100® the world's first proven natural product to repair DNA damage. Years  of clinical trials and independently published studies have confirmed his science. C-MED-100® has proven to enhance the natural DNA repair process, as well as augment the immune system in both animals and humans.

Indeed, C-MED-100® is the  first nutraceutical having FDA permission to claim natural DNA repair activity. In human studies, C-MED-100® has shown an enhanced ability to repair DNA. In animal studies, the product repaired "single strand" DNA, and also repaired the more serious "double strand" DNA damage.

CURRICULUM VITAE

EDUCATION:

  • 1962 B.A. degree (Pre medicine), University  of Vermont, Burlington, Vermont
  • 1964 MS. degree (Fungal physiology), University of Rhode Island, Kingston, Rhode Island
  • 1968 Ph.D. degree (Biological sciences), University of Rhode Island, Kingston, Rhode Island
  • 1969 Postdoctorate (Mycotoxin chemistry), North Carolina State University, Raleigh, N.C.
  • 1979 Docent in Biochemistry, University of Lund, Lund, Sweden

HONORS:

  • 1970-71 Editorial Board, National Institute of Environmental Health Sciences (USA),
  • 1971-73. Adjunct Professor (Assistant), North Carolina State University,
  • August 1981-1989 Adjunct Professor (Associate), Environmental Medicine, New York University,
  • May 10-12,1982 Chairman, American Swedish Conference on methods for genotoxicity testing in humans,
  • 1985.  Director of the PMI Strangf University of Lund Research Center and Cooperative agreement
  • July 1987  Adjunct Professor in Molecular Ecogenetics, University of Lund, Lund, Sweden, .
  • 1990.  Head of the Biological Bank and Biomarker Program for the Malm 6  Diet and Cancer Study, University of Lund, Malmb, Sweden,
  • 1991 Scientific Director, Swedish American Research Foundation, New York City, .
  • 1986 Founder of CampaMed,
  • 1994 Founder of Optigene, Inc. (NASDAQ),

BRIEF CHRONOLOGY OF EMPLOYMENT

  • 2001 to date President and Chairman CampaMed, New York City and Professor of Cell and Molecular Biology, University of Lund
  • 1993-2000 Head of the Department of Molecular Ecogenetics, University of Lund, Lund, Sweden. Chief Scientific Officer, Optigene, Inc., New York City.
  • 1989-1999 Assoc. Research Professor, NYU Medical Center, Department of Environmental Medicine, New York City.
  • 1988-2000 Chief Scientific Officer, Optigene, Inc. (NASDAQ)
  • 1987 to date Professor of Molecular Ecogenetics, University of Lund, Lund, Sweden.
  • 1982-1989 Director Division of Biochemical Epidemiology at the PMI Strang Clinic, New York City, and Head of the Department of Molecular Ecogenetics, University of Lund, Lund, Sweden., Director of Cancer Identification of individuals at risk for cancer.
  • 1976-1982 Docent in Biochemical and Genetic Ecotoxicology, Wallenberg Laboratory, University of Lund, Lund, Sweden and Research Associate, Unit for Community Care Sciences, Dalby, Sweden. Molecular mechanisms of individual variation to carcinogenic exposure.
  • 1973-1976 Research Associate, Department of Biochemistry, University of Lund, Lund, Sweden and Unit for Community Care Sciences, Dalby, Sweden. Molecular mechanisms of individual variation to carcinogenic exposure and neoplastic associated (dA) changes in DNA.
  • 1972-1973 Staff Fellow, National Institute of Environmental Health Sciences (USA). Mycotoxins and DNA biochemistry of repeated sequences.
  • 1971-1972 Research Docent, University of Lund, Lund, Sweden. Gene amplification and cell differentiation. 1969 1971 Staff Fellow, National Institute of Environmental Health Sciences (USA).  Mycotoxins

Send e-mails to:ron.pero@bdrlabs.com

BDR Principals - Dr. Arthur Banne

 

 

 

 

 

 

 

 

 

BRIEF CHRONOLOGY OF EMPLOYMENT

  • 1999 - Present Director - Biomedical Diagnostic Research, Inc. Chesterland, Ohio
  • 1995 - 2002 President and CEO - Medical Express Laboratories Cleveland, Ohio
  • 1993 - 1995 CEO - Specialty Pathology Laboratories Detroit,MI
  • 1989 - 1993 General Manager - Continental Medical Laboratory Coral Gables, FL
  • 1988 - 1989 Senior Vice President & COO - Modern Care Corporation Baltimore, MD
  • 1986 - 1988 Regional Director - National Health Laboratories (Revlon) Vienna, VA
  • 1981 - 1986 Regional Director - Metpath Laboratories (Corning) Rockville, MD
  • 1981 - 1986 CEO - Sherman Laboratories Baltimore, MD